Skip to main content
MedicHelpLine
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsOralBlack Box

WYMZYA Fe

NORETHINDRONE AND ETHINYL ESTRADIOL

Standard Dose
2 DOSAGE AND ADMINISTRATION Take one tablet by mouth at the same time every day. Tablets may be chewed or swallowed. ( 2.1 ) Take tablets in the order directed on the blister .( 2.1 ) 2.1 How to Start WYMZYA Fe WYMZYA Fe is dispensed in a blister [see HOW SUPPLIED/STORAGE AND HANDLING ( 16 )]. WYMZYA Fe may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration. 2.2 How to Take WYMZYA Fe WYMZYA Fe (white active tablets and brown placebo tablets) may be swallowed whole or chewed and swallowed. If the tablet is chewed, the patient should drink a full glass (8 ounces) of liquid immediately after swallowing. Table 1: Instructions for Administration of WYMZYA Fe Starting CHCs in women not currently using hormonal contraception (Day 1 Start or Sunday Start) Important: Consider the possibility of ovulation and conception prior to initiation of this product. Tablet Color: ● WYMZYA Fe active tablets are white (Day 1 to Day 21). ● WYMZYA Fe placebo tablets are brown (Day 22 to Day 28). Day 1 Start: ● Take first white active tablet on the first day of menses. ● Take subsequent white active tablets once daily at the same time each day for a total of 21 days. ● Take one brown placebo tablet daily for 7 days and at the same time of day that active tablets were taken. ● Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the day after taking the last inactive tablet). Sunday Start: ● Take first active tablet on the first Sunday after the onset of menses. Due to the potential risk of becoming pregnant, use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of the patient's first cycle pack of WYMZYA Fe . ● Take subsequent white active tablets once daily at the same time each day for a total of 21 days. ● Take one brown placebo tablet daily for the following 7 days and at the same time of day that active tablets were taken. ● Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the Sunday after taking the last inactive tablet) and additional non-hormonal contraceptive is not needed. Switching to WYMZYA Fe from another hormonal contraceptive Start on the same day that a new pack of the previous hormonal contraceptive would have started. Switching from another contraceptive method to WYMZYA Fe Start WYMZYA Fe : ● Transdermal patch ● On the day when next application would have been scheduled ● Vaginal ring ● On the day when next insertion would have been scheduled ● Injection ● On the day when next injection would have been scheduled ● Intrauterine contraceptive ● On the day of removal ● If the IUD is not removed on first day of the patient's menstrual cycle, additional non-hormonal contraceptive (such as condoms and spermicide) is needed for the first seven days of the first cycle pack. ● Implant ● On the day of removal Complete instructions to facilitate patient counseling on proper tablet usage are located in the FDA-Approved Patient Labeling. Starting WYMZYA Fe after Abortion or Miscarriage First-trimester: After a first-trimester abortion or miscarriage, WYMZYA Fe may be started immediately. An additional method of contraception is not needed if WYMZYA Fe is started within 5 days after termination of the pregnancy. If WYMZYA Fe is not started within 5 days after termination of the pregnancy, the patient should use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of her first cycle pack of WYMZYA Fe. Second-trimester: Do not start until 4 weeks after a second-trimester abortion or miscarriage, due to the increased risk of thromboembolic disease. Start WYMZYA Fe, following the instructions in Table 1 for Day 1 or Sunday start, as desired. If using Sunday start, use additional non- hormonal contraception (such as condoms and spermicide) for the first seven days of the patient's first cycle pack of WYMZYA Fe. [see CONTRAINDICATIONS ( 4 ), WARNINGS AND PRECAUTIONS ( 5.1 ), and FDA-APPROVED PATIENT LABELING.] Starting WYMZYA Fe after Childbirth Do not start until 4 weeks after delivery, due to the increased risk of thromboembolic disease. Start contraceptive therapy with WYMZYA Fe following the instructions in Table 1 for women not currently using hormonal contraception. If the woman has not yet had a period postpartum, consider the possibility of ovulation and conception occurring prior to use of WYMZYA Fe. [see CONTRAINDICATIONS ( 4 ), WARNINGS AND PRECAUTIONS ( 5.1 ), USE IN SPECIFIC POPULATIONS ( 8.1 and 8.3 ), and FDA-APPROVED PATIENT LABELING] . 2.3 Missed Tablets Table 2: Instructions for Missed WYMZYA Fe Tablets ● If one white active tablet is missed in Weeks 1, 2, or 3 Take the tablet as soon as possible. Continue taking one tablet a day until the pack is finished. ● If two white active tablets are missed in Week 1 or Week 2 Take the two missed tablets as soon as possible and the next two active tablets the next day. Continue taking one tablet a day until the pack is finished. Additional non-hormonal contraception (such as condoms and spermicide) should be used as back-up if the patient has sex within 7 days after missing tablets. ● If two white active tablets are missed in Week 3 or three or more white active tablets are missed in a row in Weeks 1, 2, or 3 Day 1 start : Throw out the rest of the pack and start a new pack that same day. Sunday start : Continue taking one tablet a day until Sunday, then throw out the rest of the pack and start a new pack that same day. Additional non-hormonal contraception (such as condoms and spermicide) should be used as back-up if the patient has sex within 7 days after missing tablets. 2.4 Advice in Case of Gastrointestinal Disturbances In case of severe vomiting or diarrhea, absorption may not be complete and additional contraceptive measures should be taken. If vomiting or diarrhea occurs within 3 to 4 hours after taking an active tablet, handle this as a missed tablet [see FDA-APPROVED PATIENT LABELING] .
Max Dose
See official label
Primary Use
1 INDICATIONS AND USAGE WYMZYA TM Fe is indicated for use by females of reproductive potential to prevent pregnancy.
Summary

Indications and usage 1 INDICATIONS AND USAGE WYMZYA TM Fe is indicated for use by females of reproductive potential to prevent pregnancy.

WYMZYA Fe is a progestin/estrogen COC indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Dosage and administration 2 DOSAGE AND ADMINISTRATION Take one tablet by mouth at the same time every day.

Structured Monograph

Clinical summary

Indications and usage 1 INDICATIONS AND USAGE WYMZYA TM Fe is indicated for use by females of reproductive potential to prevent pregnancy. WYMZYA Fe is a progestin/estrogen COC indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Dosage and administration 2 DOSAGE AND ADMINISTRATION Take one tablet by mouth at the same time every day. Tablets may be chewed or swallowed. ( 2.1 ) Take tablets in the order directed on the blister .( 2.1 ) 2.1 How to Start WYMZYA Fe WYMZYA Fe is dispensed in a blister [see HOW SUPPLIED/STORAGE AND HANDLING ( 16 )]. WYMZYA Fe may be started using either a Day 1 start or a Sunday start (see Table 1). For the first cycle of a Sunday Start regimen, an additional method of contraception should be used until after the first 7 consecutive days of administration. 2.2 How to Take WYMZYA Fe WYMZYA Fe (white active tablets and brown placebo tablets) may be swallowed whole or chewed and swallowed. If the tablet is chewed, the patient should drink a full glass (8 ounces) of liquid immediately after swallowing. Table 1: Instructions for Administration of WYMZYA Fe Starting CHCs in women not currently using hormonal contraception (Day 1 Start or Sunday Start) Important: Consider the possibility of ovulation and conception prior to initiation of this product. Tablet Color: ● WYMZYA Fe active tablets are white (Day 1 to Day 21). ● WYMZYA Fe placebo tablets are brown (Day 22 to Day 28). Day 1 Start: ● Take first white active tablet on the first day of menses. ● Take subsequent white active tablets once daily at the same time each day for a total of 21 days. ● Take one brown placebo tablet daily for 7 days and at the same time of day that active tablets were taken. ● Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the day after taking the last inactive tablet). Sunday Start: ● Take first active tablet on the first Sunday after the onset of menses. Due to the potential risk of becoming pregnant, use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of the patient's first cycle pack of WYMZYA Fe . ● Take subsequent white active tablets once daily at the same time each day for a total of 21 days. ● Take one brown placebo tablet daily for the following 7 days and at the same time of day that active tablets were taken. ● Begin each subsequent pack on the same day of the week as the first cycle pack (i.e., on the Sunday after taking the last inactive tablet) and additional non-hormonal contraceptive is not needed. Switching to WYMZYA Fe from another hormonal contraceptive Start on the same day that a new pack of the previous hormonal contraceptive would have started. Switching from another contraceptive method to WYMZYA Fe Start WYMZYA Fe : ● Transdermal patch ● On the day when next application would have been scheduled ● Vaginal ring ● On the day when next insertion would have been scheduled ● Injection ● On the day when next injection would have been scheduled ● Intrauterine contraceptive ● On the day of removal ● If the IUD is not removed on first day of the patient's menstrual cycle, additional non-hormonal contraceptive (such as condoms and spermicide) is needed for the first seven days of the first cycle pack. ● Implant ● On the day of removal Complete instructions to facilitate patient counseling on proper tablet usage are located in the FDA-Approved Patient Labeling. Starting WYMZYA Fe after Abortion or Miscarriage First-trimester: After a first-trimester abortion or miscarriage, WYMZYA Fe may be started immediately. An additional method of contraception is not needed if WYMZYA Fe is started within 5 days after termination of the pregnancy. If WYMZYA Fe is not started within 5 days after termination of the pregnancy, the patient should use additional non-hormonal contraception (such as condoms and spermicide) for the first seven days of her first cycle pack of WYMZYA Fe. Second-trimester: Do not start until 4 weeks after a second-trimester abortion or miscarriage, due to the increased risk of thromboembolic disease. Start WYMZYA Fe, following the instructions in Table 1 for Day 1 or Sunday start, as desired. If using Sunday start, use additional non- hormonal contraception (such as condoms and spermicide) for the first seven days of the patient's first cycle pack of WYMZYA Fe. [see CONTRAINDICATIONS ( 4 ), WARNINGS AND PRECAUTIONS ( 5.1 ), and FDA-APPROVED PATIENT LABELING.] Starting WYMZYA Fe after Childbirth Do not start until 4 weeks after delivery, due to the increased risk of thromboembolic disease. Start contraceptive therapy with WYMZYA Fe following the instructions in Table 1 for women not currently using hormonal contraception. If the woman has not yet had a period postpartum, consider the possibility of ovulation and conception occurring prior to use of WYMZYA Fe. [see CONTRAINDICATIONS ( 4 ), WARNINGS AND PRECAUTIONS ( 5.1 ), USE IN SPECIFIC POPULATIONS ( 8.1 and 8.3

Boxed Warning

WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptive (COC) use. This risk increases with age, particularly in women over 35 years of age, and with the number of cigarettes smoked. For this reason, COCs are contraindicated in women who are over 35 years of age and smoke [see CONTRAINDICATIONS ( 4 )] . WARNING: CIGARETTE SMOKING AND SERIOUS CARDIOVASCULAR EVENTS See Full Prescribing Information for complete boxed warning. WYMZYA Fe is contraindicated in women over 35 years old who smoke. ( 4 ) Cigarette smoking increases the risk of serious cardiovascular events from combination oral contraceptives (COC) use. ( 4 )

Monitoring

  • 5 WARNINGS AND PRECAUTIONS Thrombotic Disorders and Other Vascular Problems: Stop WYMZYA Fe if a thrombotic event occurs.
  • Stop at least 4 weeks before through 2 weeks after major surgery.
  • Start no earlier than 4 weeks after delivery, in women who are not breastfeeding ( 5.1 ) Liver disease : Discontinue WYMZYA Fe if jaundice occurs ( 5.2 ) High blood pressure : If used in women with well-controlled hypertension, monitor blood pressure and stop WYMZYA Fe if blood pressure rises significantly.
  • ( 5.4 ) Carbohydrate and lipid metabolic effects : Monitor prediabetic and diabetic women taking WYMZYA Fe.

Interaction Notes

  • 7 DRUG INTERACTIONS Consult the labeling of concurrently used drugs to obtain further information about interactions with hormonal contraceptives or the potential for enzyme alterations.
  • Drugs or herbal products that induce certain enzymes, including CYP3A4, may decrease the effectiveness of COCs or increase breakthrough bleeding.
  • Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with COCs ( 7.1 ) 7.1 Effects of Other Drugs on Combined Oral Contraceptives Substances Decreasing the Plasma Concentrations of COCs and Potentially Diminishing the Efficacy of COCs Drugs or herbal products that induce certain enzymes, including cytochrome P450 3A4 (CYP3A4), may decrease the plasma concentrations of COCs and potentially diminish the effectiveness of COCs or increase breakthrough bleeding.
  • Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, and products containing St.